GLS 5300

Drug Profile

GLS 5300

Alternative Names: GLS5300; MERS DNA vaccine - Inovio; MERS vaccine - GeneOne

Latest Information Update: 25 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Inovio Pharmaceuticals
  • Developer GeneOne Life Science; Inovio Pharmaceuticals; Walter Reed Army Institute of Research
  • Class Antivirals; DNA vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Middle East respiratory syndrome coronavirus

Most Recent Events

  • 18 Sep 2017 Immunogenicity data from a phase I trial in Middle east respiratory syndrome released by Inovio Pharmaceuticals
  • 18 Sep 2017 Inovio Pharmaceuticals plans a phase I/IIa trial for Middle east respiratory syndrome in South Korea in 2017
  • 18 Sep 2017 Inovio Pharmaceuticals receives approval from the Korean Ministry of Food and Drug Safety for a phase I/IIa trial of GLS 5300 for Middle east respiratory syndrome in South Korea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top